Gastric Cancer Stage III

Camrelizumab, 200 mg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.

Camrelizumab

Tegafur-gimeracil-oteracil potassium: 80 - 120 mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.

Docetaxel: 40 mg/m^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.

Docetaxel

Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiaotong University

A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer

A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 Sequenced by Camrelizumab+S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer (PD-L1 + / MSI-H / EBV +/dMMR)

zhaogang

Deputy director of gastrointestinal surgery administration

RenJi Hospital

Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period

Serum and plasma of samples were than seperated and stored at -80 ºC until the assay. Serum phosphorus (P) and calcium (Ca) were measured by Ion selective electrode (ISE) and alkaline phosphatase (ALP) activity was measured by kinetic enzymatic method, with reagents of Beckman Coulter, on an auto-analyser (Olympus AU5400, Beckman Coulter, Inc., U.S.A.). Serum intact parathormone (iPTH) was analyzed by two-site immunoenzymatic method and 25-hidroxy D levels were analyzed by competetive immunoenzymatic method on UniCel DxI 800 Immunoassay System (Beckman Coulter, Inc., U.S.A.).

Hyperemesis Gravidarum

DEXA

Hyperemesis Gravidarum and Osteoporosis

Is Hyperemesis Gravidarum a Risk Factor for Osteoporosis ?

All patients were performed on a standard dual energy x-ray absorptiometry (DEXA, Hologic Discovery Wi S/N 80848) during early postpartum period ( frequently in two days after birth before discharge of patients) by a single technician to assess osteoporosis. Blood samples include laboratory parameters associated with osteoporosis (Vitamin D, ALP, P, Ca and PTH).

Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period and collected into ethylenediaminetetraacetate (EDTA) containing sterile tubes and serum separator tubes (SSTs) to assess osteoporosis. Blood samples include laboratory parameters associated with osteoporosis (Vitamin D, ALP, P, Ca and PTH).

Gulsum Uysal

Medical doctor

Adana Numune Training and Research Hospital

Vitamin D Deficiency

Iodine Deficiency

Hypothyroidism

Rickets

Lead Intoxication

Kay Mackenson Clinic

FHADIMAC

Vitamin D, Iodine, and Lead Levels in Haitian Infants and Children.

Vitamin D Deficiency, Iodine Deficiency and Lead Levels in Haitian Infants and Children.

Measure serum 25OHD levels, including the proportion of children found to be vitamin D insufficient, deficient and severely deficient.

Urinary iodine levels, including the proportion of children found to be iodine deficient

Serum lead levels in Haitian infants and children

The number of vitamin D deficient children found to have elevated alkaline phosphatase levels (as a proxy for vitamin D deficient rickets)

to measure the influence of dietary vitamin D intake and sun exposure on vitamin D levels.

The 25OHD levels were measured via serum and POCT device to compare accuracy of the POCT device.

The number of children found to have goiters and/or abnormal thyroid function tests

Number of children with elevated levels of urinary perchlorate and/or thiocyanate

Evaluation of the extent of childhood lead poisoning using the CDC definition of lead poisoning, (BLL) ≥ 10 µg/dL

Julia Von Oettingen

Fellow in Pediatric Endocrinology

Boston Children’s Hospital

Fondation Haitienne de Diabete et de Maladies Cardiovasculaires (FHADIMAC)

Kay Mackenson Clinic, Inc.

Hypercholesterolemia

3,5-Diiodothyropropionic acid (DITPA) therapy

Johns Hopkins Bayview Medical Center

Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients

A Randomized, Double-Blind Placebo-Controlled Study of 3,5-diiodothyropropionic Acid (DITPA) in Combination With Standard Therapy to Attain NCEP ATP III Goal for LDL Cholesterol in Hypercholesterolemic Patients

hyperthyroidism/phosphatase

A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer

Hyperemesis Gravidarum and Osteoporosis

Vitamin D, Iodine, and Lead Levels in Haitian Infants and Children.

Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı